Allergy:欧洲变应性鼻炎的用药模式如何?一款应用程序MASK-air®的真实数据揭晓答案

2022-03-18 小文子 MedSci原创

变应性鼻炎患者的用药模式在欧洲各地区相似,联合用药很常见,且呈现季节性(春季尤其频繁)。

联合用药在变应性鼻炎(AR)患者中很常见,但具体用药模式尚不清楚。一项研究利用欧洲国家的一款应用程序MASK-air®收集的真实数据评估变应性鼻炎联合用药模式及其欧洲区域模式。

研究纳入2015年5月21日至2020年12月6日期间,欧洲MASK-air®用户(18个不同国家)的每日监测数据。使用者年龄为16~90岁,自我报告诊断为变应性鼻炎。对每日监测MASK-air®的不同药物方案进行了横断面描述性分析,包括每种药物的使用频率,以及联合用药频率。

研究分析了2015~2020年MASK-air®欧洲数据。使用视觉模拟量表(VAS)比较了未用药、单药治疗和联合用药情况下的总体过敏症状(VAS过敏症状),以及对工作的影响。评估了每月不同药物方案的使用情况以及一年内每位患者报告的不同药物的平均数量。

研究分析了222025天的数据,102202天(46.0%)涉及至少一种药物的使用,纳入13122名使用者。其中,119823天内(占总天数的54.0%)未使用任何药物,单药治疗63887天(28.8%)和联合用药38315天(17.3%)。每位患者报告每年平均使用2.7种药物,80%的患者报告使用两种或两种以上药物。

单药治疗,最常使用的有口服抗组胺药OAH(34481天;54.0%)、鼻用糖皮质激素INCS(13050天;20.4%)和氮斯汀/氟替卡松复方制剂AzeFlu(8928天;14.0%)。在同一天(10974天;28.6%),联合用药OAH和INCS的频率更高。

未用药治疗的VAS过敏症状中位天数为7天,单药治疗为14天,联合用药为21天(p<0.01)。

研究观察到药物使用高峰出现在春季。报告用药天数的百分比在6月份最高(54.5%),在1月份最低(34.9%)。

变应性鼻炎患者的用药模式在欧洲各地区相似,联合用药很常见,且呈现季节性(春季尤其频繁)。研究表明变应性鼻炎患者根据自己的症状进行治疗,而不是遵循疾病治疗指南。医生应该意识到,大多数患者没有按照处方进行治疗,在与患者讨论治疗方案时,应该调整共同决策。

原文出处:

Sousa- Pinto B, Sá- Sousa A, Vieira RJ, et al. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK- air® real- world data. Allergy. 2022;00:1– 13. doi:10.1111/all.15275.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085419, encodeId=0db62085419c9, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Sep 02 02:51:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323331, encodeId=c2961323331bb, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329605, encodeId=380e13296050e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339448, encodeId=e43413394486b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085419, encodeId=0db62085419c9, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Sep 02 02:51:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323331, encodeId=c2961323331bb, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329605, encodeId=380e13296050e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339448, encodeId=e43413394486b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085419, encodeId=0db62085419c9, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Sep 02 02:51:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323331, encodeId=c2961323331bb, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329605, encodeId=380e13296050e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339448, encodeId=e43413394486b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-20 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085419, encodeId=0db62085419c9, content=<a href='/topic/show?id=e60c4934345' target=_blank style='color:#2F92EE;'>#应用程序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49343, encryptionId=e60c4934345, topicName=应用程序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Sep 02 02:51:07 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323331, encodeId=c2961323331bb, content=<a href='/topic/show?id=5332380998f' target=_blank style='color:#2F92EE;'>#变应性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38099, encryptionId=5332380998f, topicName=变应性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329605, encodeId=380e13296050e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339448, encodeId=e43413394486b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Mar 20 08:51:07 CST 2022, time=2022-03-20, status=1, ipAttribution=)]

相关资讯

3分钟看懂冻疮的发病机制和治疗

冻疮指寒冷所致比较严重局限性皮肤炎症损害。冻疮的发病机制、用药盘点来了!

官方明确:诊所、卫生室可用药再扩大(附名单)

基层医疗服务机构属于整个医疗服务系统中一个重要的组成部分,同时承担着大多数基层医疗服务活动。

房颤治疗用药速记手册!心内科医生必备~

心房颤动(简称房颤)是临床上最常见的心律失常。房颤发作时,心房率快且不规则,心房失去有效的收缩功能,进而导致心室率紊乱,影响心脏的泵血功能。随着年龄的增长,房颤的发生率也不断升高。

高血压15种合并症的首选药和禁用药

常用降压药物包括二氢吡啶类钙通道阻滞剂(CCB)、血管紧张素转化酶抑制剂(ACEI)、血管紧张素受体拮抗剂(ARB)、利尿剂和β受体阻滞剂五类。CCB:氨氯地平、尼群地平等;ACEI:依那普